首页> 外文期刊>Biomedical materials >Omentum ECM-based hydrogel as a platform for cardiac cell delivery
【24h】

Omentum ECM-based hydrogel as a platform for cardiac cell delivery

机译:大网膜基于ECM的水凝胶作为心脏细胞递送的平台

获取原文
获取原文并翻译 | 示例
       

摘要

Cardiovascular diseases remain the number one killer in Western countries. Despite recent advances and promising results in cardiac cell-based therapy, one of the remaining challenges is poor cell retention in the desired site. As a solution, cell delivery systems are developed to ensure that a sufficient number of viable cells reach the infarct area. These delivery systems are based on biomaterials that provide a surrogate microenvironment for the encapsulated cells, retaining them in the desired location post-delivery. Injectable thermoresponsive ECM-based hydrogels have been developed to achieve this goal. Unfortunately, the use of allogeneic or xenogeneic ECM may hamper the treatment due to an immune response to residual cellular content from the host. In this work, we have developed an omentum-based hydrogel capable of self-assembly under physiological conditions. Although in this study the omentum was obtained from porcine sources, it can be easily and safely extracted from the patient, serving as an autologous protective vehicle for the transported cells. We have characterized the biochemical composition, mechanical properties, and gelation and degradation kinetics of the processed biomaterial. Furthermore, the ability of the hydrogel to encapsulate cardiac cells and support their culture was evaluated. We envision that the newly developed platform may open new opportunities for personalized cell delivery to the heart and other tissues.
机译:心血管疾病仍然是西方国家的头号杀手。尽管基于心脏细胞疗法的最新进展和令人鼓舞的结果,仍然存在的挑战之一是在所需部位的细胞滞留性差。作为解决方案,开发了细胞递送系统以确保足够数量的活细胞到达梗塞区域。这些递送系统基于生物材料,该生物材料为囊封的细胞提供替代性微环境,从而在递送后将其保留在所需的位置。已开发出可注射的热响应性基于ECM的水凝胶来实现此目标。不幸的是,由于对来自宿主的残余细胞含量的免疫应答,异体或异种ECM的使用可能会阻碍治疗。在这项工作中,我们开发了一种能够在生理条件下自组装的基于网膜的水凝胶。尽管在这项研究中,大网膜是从猪中获得的,但它可以从患者中轻松安全地提取出来,作为运输细胞的自体保护载体。我们已经表征了已加工生物材料的生化组成,机械性能以及胶凝和降解动力学。此外,评估了水凝胶包封心脏细胞并支持其培养的能力。我们设想,新开发的平台可能为个性化细胞递送至心脏和其他组织开辟新的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号